Cancer risk associated with insulin Glargine among adult type 2 diabetes patients - a nationwide Cohort study

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Chang, Chia Hsuin ^a,b   Toh, Sengwee ^c   Lin, Jou Wei ^b   Chen, Shu Ting ^a   Kuo, Chuei Wen ^d   Chuang, Lee Ming ^a,b   Lai, Mei Shu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d National Health Insurance Mediation Committee   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; GLARGINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPEROSMOLARITY; KETOACIDOSIS; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PERIPHERAL VASCULAR DISEASE; PROSTATE CANCER; RETINOPATHY; RETROSPECTIVE STUDY; SKIN CANCER; STOMACH CANCER; TREATMENT RESPONSE; MIDDLE AGED; NEOPLASM; PANCREAS TUMOR; PROSTATE TUMOR;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79959603817     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021368     Document Type: Article

References (19)

1. Smith U, Gale EAM, (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52: 1699-1708.
2. Pollak M, Russell-Jones D, (2010) Insulin analogues and cancer risk: cause for concern or cause celebre? Int J Clin Pract 64: 628-636.
3. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H, (2008) Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25: 41-49.
4. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, et al. (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52: 1778-1788.
5. Home PD, Lagarenne P, (2009) Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52: 2499-2506.
6. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744.
7. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, et al. (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabet Care doi:10.2337/dc10-0476.
8. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, et al. (2009) Insulin glargine use and short-term incidence of malignancies - a population-based follow-up study in Sweden. Diabetologia 52: 1745-1754.
9. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755-1765.
10. Currie CJ, Poole CD, Gale EAM, (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
11. Hernandez-Diaz S, Adami H-O, (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53: 802-808.
12. Pocock S, Smeeth L, (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374: 511-513.
13. Grote VA, Becker S, Kaaks R, (2010) Diabetes mellitus type 2 - an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 118: 4-8.
14. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and Cancer: a consensus report. CA Cancer J Clin 60: 207-221.
15. Robins JM, Hernan MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
16. Schneeweiss S, (2010) A basic design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 19: 858-868.
17. Ray WA, (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: 915-20.
18. Erbel S, Reers C, Eckstein VW, Kleeff J, Buchler MW, et al. (2008) Proliferation of Colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabet Care 31: 1105-1111.
19. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. Available from http://www.whocc.no/ddd/definition_and_general_considera/, accessed 29 Oct 2010.